Перевести на Переведено сервисом «Яндекс.Перевод»

Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Gilead Sciences Inc. Deutsche Bank Buy 124
HCA Holdings, Inc. UBS Buy 90
Humana Inc. Barclays Buy 223
Intuitive Surgical, Inc. Barclays Buy 625
Johnson & Johnson Deutsche Bank Buy 105
Mallinckrodt Public Limited Company Barclays Buy 80
Merck & Co. Inc. UBS Buy 68
Mylan N.V. Barclays Buy 57
PerkinElmer Inc. UBS Buy 60
Pfizer Inc. Morgan Stanley Buy 43
Regeneron Pharmaceuticals, Inc. Barclays Buy 593
St. Jude Medical Inc. Deutsche Bank Buy 77
Stryker Corporation Argus Buy 120
Thermo Fisher Scientific, Inc. Argus Buy 145
UnitedHealth Group Incorporated Morgan Stanley Buy 140
Universal Health Services Inc. Barclays Buy 150
Vertex Pharmaceuticals Incorporated Argus Buy 155
Waters Corporation BofA/Merrill Buy 140
1 2